Failure of long-term cyproheptadine therapy in lowering growth hormone levels in acromegaly.
Basal and post-glucose growth hormone (GH) responses were evaluated in 10 acromegalics receiving cyproheptadine (cypro) 4 mg 6 hourly at 2 and 21 days after initiating therapy. Of the 10 patients, six had macroadenomas with varying degree of suprasellar extensions, one a microadenoma and three had persistent hypersomatotropism despite pituitary adenomectomy due to residual tumour. The basal and post-glucose GH showed no significant change in all, except one with a pituitary microadenoma. His GH was reduced from 680 to 108 mU/L on the second and 82 mU/l on the 21st day of cypro therapy. These data do not suggest any therapeutic role of cypro in the management of acromegaly.
Dash
R J
RJ
Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Ahmad
J
J
Sethi
B K
BK
Sialy
R
R
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D003533:Cyproheptadine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000494:pharmacology; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D003533:Cyproheptadine; D013006:Growth Hormone; D005947:Glucose